AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9535242 — intervention group
Group type: COMPARATOR
Intervention: No medication
Number of subjects: 38
Study 7833191 — intervention group
Group type: EXPERIMENTAL
Intervention: Flucloxacillin (or clindamycin if allergic to penicillin)
Number of subjects: 473
Study 7833191 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 473
Study 3404500 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition of arousal
Number of subjects: 2
Study 3404500 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition of relaxation
Number of subjects: 2
Study 29768414 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose autologous AdMSC (1x10^6 cells/kg)
Number of subjects: 34
Study 29768414 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose autologous AdMSC (4x10^6 cells/kg)
Number of subjects: 34
Study 29768414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 27261416 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon Sinuplasty
Number of subjects: 0
Study 27261416 — intervention group
Group type: COMPARATOR
Intervention: Uncinectomy
Number of subjects: 0
Study 25634162 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthrinses with sucrose or NaCl
Number of subjects: 10
Study 25634162 — intervention group
Group type: COMPARATOR
Intervention: Mouthrinses without additives
Number of subjects: 10
Study 25634162 — intervention group
Group type: EXPERIMENTAL
Intervention: All mouthrinses tested
Number of subjects: 10
Study 24278924 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants placed at the bone level (Group 0)
Number of subjects: 30
Study 24278924 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants placed 1 mm below the alveolar crest (Group 1)
Number of subjects: 30
Study 24278924 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants placed 2 mm below the alveolar crest (Group 2)
Number of subjects: 30
Study 24278924 — intervention group
Group type: COMPARATOR
Intervention: Implants in groups 1 and 2 compared to Group 0
Number of subjects: 30
Study 21929307 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy (fludarabine and cyclophosphamide with rituximab)
Number of subjects: 100
Study 21929307 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (fludarabine and cyclophosphamide without rituximab)
Number of subjects: 100
Study 19099859 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol plus traditional regimen (digoxin, prednisone and/or diuretics)
Number of subjects: 21
Study 19099859 — intervention group
Group type: COMPARATOR
Intervention: Traditional regimen (digoxin, prednisone and/or diuretics)
Number of subjects: 21
Study 11841719 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine-Adcon-L (M-ADL)
Number of subjects: 100
Study 9800931 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone enanthate
Number of subjects: 180
Study 9800931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 8087777 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbidity assessment in cancer patients
Number of subjects: 1712
Study 8087777 — intervention group
Group type: EXPERIMENTAL
Intervention: Data collection on current medications
Number of subjects: 1712
Study 8087777 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot study results
Number of subjects: 1712
Study 8087777 — intervention group
Group type: EXPERIMENTAL
Intervention: Full study planned
Number of subjects: 1712
Study 2763389 — intervention group
Group type: EXPERIMENTAL
Intervention: Parietal cell vagotomy (PCV)
Number of subjects: 106
Study 2763389 — intervention group
Group type: COMPARATOR
Intervention: Truncal vagotomy (TV)
Number of subjects: 106
Study 578772 — intervention group
Group type: EXPERIMENTAL
Intervention: Etozolin (400 mg)
Number of subjects: 8
Study 578772 — intervention group
Group type: EXPERIMENTAL
Intervention: Etozolin (1200 mg)
Number of subjects: 8
Study 578772 — intervention group
Group type: EXPERIMENTAL
Intervention: Vs (75 mg)
Number of subjects: 8
Study 578772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 578772 — intervention group
Group type: EXPERIMENTAL
Intervention: Etozolin and Vs
Number of subjects: 8
Study 27896440 — intervention group
Group type: EXPERIMENTAL
Intervention: Treosulfan intravenous (i.v.) 7000 mg/m2 d1 q4w
Number of subjects: 250
Study 27896440 — intervention group
Group type: COMPARATOR
Intervention: Treosulfan oral (p.o.) 600 mg/m2 d1-28 q8w
Number of subjects: 250
Study 27896440 — intervention group
Group type: EXPERIMENTAL
Intervention: Treosulfan intravenous (i.v.)
Number of subjects: 250
Study 27896440 — intervention group
Group type: COMPARATOR
Intervention: Treosulfan oral (p.o.)
Number of subjects: 250
Study 25702777 — intervention group
Group type: EXPERIMENTAL
Intervention: Human recombinant erythropoietin (HRE) 80,000 IU
Number of subjects: 600
Study 25702777 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 600
Study 25702777 — intervention group
Group type: EXPERIMENTAL
Intervention: Human recombinant erythropoietin (HRE)
Number of subjects: 600
Study 23417891 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurolidine solution
Number of subjects: 112
Study 23417891 — intervention group
Group type: COMPARATOR
Intervention: Heparin solution
Number of subjects: 112
Study 23417891 — intervention group
Group type: COMPARATOR
Intervention: Standard group (Heparin)
Number of subjects: 112
Study 23417891 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (Taurolidine)
Number of subjects: 112
Study 23417891 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 112
Study 21131070 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital inclusion program (computer learning workshop 'Idosos On‐Line')
Number of subjects: 42
Study 21131070 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 42
Study 19352154 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprixx GJ device (Harbor Medical Inc., Santa Barbara, CA)
Number of subjects: 114
Study 19352154 — intervention group
Group type: COMPARATOR
Intervention: Control group (no device)
Number of subjects: 114
Study 16919063 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactory hypersensitivity (OHS) in migraine patients
Number of subjects: 74
Study 16919063 — intervention group
Group type: COMPARATOR
Intervention: Control group (30 subjects)
Number of subjects: 74
Study 15601961 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-carbohydrate (VLC) diet
Number of subjects: 4
Study 15601961 — intervention group
Group type: COMPARATOR
Intervention: Low-fat (LF) diet
Number of subjects: 4
Study 11323348 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiar instances (exemplars) from two categories (Experimental group)
Number of subjects: 82
Study 11323348 — intervention group
Group type: COMPARATOR
Intervention: Bird sounds (Control group)
Number of subjects: 82
Study 11323348 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Experimental and Control)
Number of subjects: 82
Study 9155592 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral theophylline (240 mg)
Number of subjects: 28
Study 8292702 — intervention group
Group type: COMPARATOR
Intervention: Halothane 1 MAC (group I, n = 10)
Number of subjects: 20
Study 8292702 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane 1 MAC (group II, n = 10)
Number of subjects: 20
Study 8292702 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone 0.5 mg/kg (after halothane and isoflurane)
Number of subjects: 20
Study 29894374 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction intervention; 20 weekly, 1.5-hour sessions
Number of subjects: 44
Study 27770787 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized virgin olive oil with high phenolic content (OVOO, 429 mg/Kg)
Number of subjects: 18
Study 27770787 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional olive oil (FOO, 429 mg/Kg phenolic compounds, 389 mg/Kg triterpenic acids)
Number of subjects: 18
Study 27770787 — intervention group
Group type: COMPARATOR
Intervention: Standard virgin olive oil (VOO)
Number of subjects: 18
Study 24430787 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention and treatment with voglibose or nateglinide
Number of subjects: 302
Study 24430787 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressors (n=64)
Number of subjects: 302
Study 24430787 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis
Number of subjects: 302
Study 21948857 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary incontinence (including urge and stress incontinence)
Number of subjects: 5474
Study 21948857 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume of urine lost
Number of subjects: 5474
Study 21948857 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of urinary symptoms
Number of subjects: 5474
Study 21948857 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical limitations
Number of subjects: 5474
Study 21948857 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 5474
Study 20337620 — intervention group
Group type: EXPERIMENTAL
Intervention: C-MAC laryngoscope
Number of subjects: 31
Study 20337620 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 31
Study 20337620 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq laryngoscope
Number of subjects: 31
Study 20337620 — intervention group
Group type: EXPERIMENTAL
Intervention: Glidescope laryngoscope
Number of subjects: 31
Study 19922569 — intervention group
Group type: EXPERIMENTAL
Intervention: Check Your Drinking (CYD) screener
Number of subjects: 185
Study 19922569 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control group
Number of subjects: 185
Study 16830374 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzymatic detergent
Number of subjects: 260
Study 16830374 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine
Number of subjects: 260
Study 12582226 — intervention group
Group type: EXPERIMENTAL
Intervention: Long break group (LB) - 6-week break after lesson 7
Number of subjects: 142
Study 12582226 — intervention group
Group type: EXPERIMENTAL
Intervention: Short break group (SB) - 2-week breaks after lessons 3, 6, and 9
Number of subjects: 142
Study 12582226 — intervention group
Group type: COMPARATOR
Intervention: Control group - standard behavioral weight loss program with 14 weekly sessions
Number of subjects: 142
Study 10852458 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline (CAB) treatment at doses ranging from 0.25-3.5 mg weekly for 1-3 years
Number of subjects: 110
Study 10852458 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline (CAB) treatment at doses ranging from 0.25-1 mg weekly for 1-6 months
Number of subjects: 110
Study 10852458 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline (CAB) treatment at doses ranging from 1-2 mg weekly for 6-12 months and 3-3.5 mg weekly for 18-24 months
Number of subjects: 110
Study 10852458 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline (CAB) treatment at doses ranging from 1-2 mg weekly for 1-6 months and 3 mg weekly for 12 months
Number of subjects: 110
Study 9356099 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) infused intravenously at a rate of 0.3 g/kg
Number of subjects: 24
Study 9356099 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NTG) infused intravenously at a rate of 5 g/kg
Number of subjects: 24
Study 8449049 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol by nebulizer plus placebo by inhaler (n = 20)
Number of subjects: 35
Study 8449049 — intervention group
Group type: COMPARATOR
Intervention: Albuterol by inhaler plus placebo by nebulizer (n = 15)
Number of subjects: 35
Study 3756264 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 100
Study 3756264 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 100
Study 3756264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 29873864 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal therapy (personalized oral hygiene instructions, subgingival scaling, and root planing per quadrant)
Number of subjects: 69
Study 29873864 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal therapy
Number of subjects: 69
Study 29873864 — intervention group
Group type: COMPARATOR
Intervention: Control group (received equal treatment after the study period)
Number of subjects: 69
Study 26842790 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine e-cigarettes
Number of subjects: 0
Study 26842790 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine-free e-cigarettes
Number of subjects: 0
Study 26842790 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study 24878942 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 65
Study 24878942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 22244462 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard monitoring plus capnography
Number of subjects: 27
Study 22244462 — intervention group
Group type: COMPARATOR
Intervention: Standard monitoring (control group)
Number of subjects: 27
Study 20190383 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 minutes of side‐alternating whole‐body vibration (WBV; Vibraflex Home Edition II, Orthometrix Inc) per school day in addition to their school physiotherapy program
Number of subjects: 20
Study 20190383 — intervention group
Group type: COMPARATOR
Intervention: Control group (continued school physiotherapy program unchanged)
Number of subjects: 20
Study 18779620 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalent diabetes
Number of subjects: 1554
Study 18779620 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight
Number of subjects: 1554
Study 16138517 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer plus education (PE)
Number of subjects: 87
Study 16138517 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer (P)
Number of subjects: 87
Study 16138517 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 87
Study 11823390 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraosseous lidocaine (IL)
Number of subjects: 100
Study 11823390 — intervention group
Group type: COMPARATOR
Intervention: Intravenous nalbuphine and propacetamol (NP)
Number of subjects: 100
Study 10065346 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release lithium carbonate (HP matrix)
Number of subjects: 12
Study 10065346 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release lithium carbonate (L matrix)
Number of subjects: 12
Study 10065346 — intervention group
Group type: COMPARATOR
Intervention: High-fat diet
Number of subjects: 12
Study 10065346 — intervention group
Group type: COMPARATOR
Intervention: High-fat/high-protein diet
Number of subjects: 12
Study 10065346 — intervention group
Group type: COMPARATOR
Intervention: Fasting condition
Number of subjects: 12
Study 7668664 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarion cochlear implant
Number of subjects: 50
Study 7668664 — intervention group
Group type: COMPARATOR
Intervention: Nucleus implant
Number of subjects: 50
Study 7668664 — intervention group
Group type: COMPARATOR
Intervention: Ineraid device
Number of subjects: 50
Study 2343859 — intervention group
Group type: EXPERIMENTAL
Intervention: Certified mailing in phase 1
Number of subjects: 12233
Study 2343859 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat certified mailing to nonrespondents
Number of subjects: 12233
Study 2343859 — intervention group
Group type: COMPARATOR
Intervention: Altering the physical appearance of the envelope and using other postal rates
Number of subjects: 12233
Study 6777233 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hyperalimentation (IVH) with total bowel rest
Number of subjects: 36
Study 6777233 — intervention group
Group type: COMPARATOR
Intervention: Control group (prednisone 40 mg/day)
Number of subjects: 36
Study 30635497 — intervention group
Group type: EXPERIMENTAL
Intervention: Interscalene block (ISB)
Number of subjects: 44
Study 30635497 — intervention group
Group type: COMPARATOR
Intervention: Costoclavicular block (CCB)
Number of subjects: 44
Study 28655016 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 504
Study 28655016 — intervention group
Group type: COMPARATOR
Intervention: Sham electroacupuncture
Number of subjects: 504
Study 25879794 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline injection
Number of subjects: 12
Study 25879794 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline injection (control)
Number of subjects: 12
Study 24015983 — intervention group
Group type: EXPERIMENTAL
Intervention: CARE program
Number of subjects: 50
Study 24015983 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 50
Study 21868730 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg recombinant tissue-type plasminogen activator (rtPA)
Number of subjects: 48
Study 21868730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 19154802 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral erythromycin (EM) 600 mg/day, n=18
Number of subjects: 32
Study 19154802 — intervention group
Group type: COMPARATOR
Intervention: Placebo, n=14
Number of subjects: 32
Study 17356094 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg bid of nebulized recombinant human deoxyribonuclease (rhDNase)
Number of subjects: 225
Study 17356094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study 14681504 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 3047
Study 14681504 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 3047
Study 14681504 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 3047
Study 14681504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3047
Study 11106230 — intervention group
Group type: EXPERIMENTAL
Intervention: XR9576 2.0 mg/kg i.v.
Number of subjects: 0
Study 11106230 — intervention group
Group type: EXPERIMENTAL
Intervention: XR9576 > or = 200 mg/volunteer p.o.
Number of subjects: 0
Study 11106230 — intervention group
Group type: EXPERIMENTAL
Intervention: XR9576 (various doses)
Number of subjects: 0
Study 11106230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10173443 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient rehabilitation (n = 43)
Number of subjects: 85
Study 10173443 — intervention group
Group type: COMPARATOR
Intervention: Outpatient follow-up (n = 42)
Number of subjects: 85
Study 10173443 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient rehabilitation
Number of subjects: 85
Study 8443849 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal ketamine 6 mg.kg‐1
Number of subjects: 86
Study 8443849 — intervention group
Group type: COMPARATOR
Intervention: Promethazine and meperidine 1 mg.kg‐1 each (Control)
Number of subjects: 86
Study 3784306 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen (K)
Number of subjects: 2
Study 3784306 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (I)
Number of subjects: 2
Study 3784306 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects (control group)
Number of subjects: 2
Study 31023553 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation
Number of subjects: 132
Study 31023553 — intervention group
Group type: COMPARATOR
Intervention: Invalidation
Number of subjects: 132
Study 31023553 — intervention group
Group type: COMPARATOR
Intervention: Technical language
Number of subjects: 132
Study 31023553 — intervention group
Group type: COMPARATOR
Intervention: Plain language
Number of subjects: 132
Study 30629148 — intervention group
Group type: EXPERIMENTAL
Intervention: PAMVAC-GLA-SE
Number of subjects: 36
Study 30629148 — intervention group
Group type: EXPERIMENTAL
Intervention: PAMVAC with Alhydrogel or GLA-based adjuvants
Number of subjects: 36
Study 30629148 — intervention group
Group type: EXPERIMENTAL
Intervention: All PAMVAC formulations
Number of subjects: 36
Study 28110412 — intervention group
Group type: EXPERIMENTAL
Intervention: KDIGO bundle (optimization of volume status and hemodynamics, avoidance of nephrotoxic drugs, preventing hyperglycemia)
Number of subjects: 100
Study 28110412 — intervention group
Group type: EXPERIMENTAL
Intervention: KDIGO bundle
Number of subjects: 100
Study 28110412 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 100
Study 25777987 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based training for DMV staff
Number of subjects: 0
Study 25777987 — intervention group
Group type: COMPARATOR
Intervention: Control group (DMV staff without training)
Number of subjects: 0
Study 23804191 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 1754
Study 23804191 — intervention group
Group type: COMPARATOR
Intervention: PCV7
Number of subjects: 1754
Study 21094532 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS) service
Number of subjects: 312
Study 21094532 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical keyworker relationship
Number of subjects: 312
Study 21094532 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of work history
Number of subjects: 312
Study 21094532 — intervention group
Group type: EXPERIMENTAL
Intervention: Care needs being met
Number of subjects: 312
Study 21094532 — intervention group
Group type: EXPERIMENTAL
Intervention: Social disability and remission
Number of subjects: 312
Study 21094532 — intervention group
Group type: EXPERIMENTAL
Intervention: Same sex as the client
Number of subjects: 312
Study 21094532 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of the relationship
Number of subjects: 312
Study 21094532 — intervention group
Group type: EXPERIMENTAL
Intervention: Client's increasing anxiety
Number of subjects: 312
Study 21094532 — intervention group
Group type: EXPERIMENTAL
Intervention: Client and professional ratings
Number of subjects: 312
Study 19846001 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP 0 cm H(2)O
Number of subjects: 30
Study 19846001 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP 5 cm H(2)O
Number of subjects: 30
Study 19846001 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP 10 cm H(2)O
Number of subjects: 30
Study 19846001 — intervention group
Group type: COMPARATOR
Intervention: Control group at PEEP 0 cm H(2)O
Number of subjects: 30